Yat Sun Or

2021

In 2021, Yat Sun Or earned a total compensation of $2M as Senior Vice President, Research & Development, Chief Scientific Officer at Enanta Pharmaceuticals, a 8% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$224,010
Option Awards$652,535
Salary$486,525
Stock Awards$609,830
Other$19,211
Total$1,992,111

Or received $652.5K in option awards, accounting for 33% of the total pay in 2021.

Or also received $224K in non-equity incentive plan, $486.5K in salary, $609.8K in stock awards and $19.2K in other compensation.

Rankings

In 2021, Yat Sun Or's compensation ranked 6,063rd out of 12,397 executives tracked by ExecPay. In other words, Or earned more than 51.1% of executives.

ClassificationRankingPercentile
All
6,063
out of 12,397
51st
Division
Manufacturing
2,560
out of 5,492
53rd
Major group
Chemicals And Allied Products
1,118
out of 2,367
53rd
Industry group
Drugs
997
out of 2,090
52nd
Industry
Pharmaceutical Preparations
719
out of 1,537
53rd

Pay ratio

Yat Sun Or's Pay$1,992,111
Median Employee's Pay$230,731
Pay Ratio

9

to 1

In 2021, the annual total compensation of Yat Sun Or was $1,992,111.

The annual total compensation of the median employee at Enanta Pharmaceuticals was $230,731.

The ratio of Yat Sun Or's pay to the pay of median employee was therefore 9 to one.

Source: SEC filing on January 21, 2022.

Or's colleagues

We found five more compensation records of executives who worked with Yat Sun Or at Enanta Pharmaceuticals in 2021.

2021

Jay Luly

Enanta Pharmaceuticals

Chief Executive Officer

2021

Brendan Luu

Enanta Pharmaceuticals

Senior Vice President, Business Development

2021

Tara Kieffer

Enanta Pharmaceuticals

Senior Vice President, New Product Strategy & Development

2021

Nathaniel Gardiner

Enanta Pharmaceuticals

General Counsel

2021

Paul Mellett

Enanta Pharmaceuticals

Chief Financial Officer

News

You may also like